Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
2013年8月1日 更新者:Human Genome Sciences Inc.
A Phase 2, Multi-Center, Open-Label, Randomized Study of Mapatumumab (TRM-1 [HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (MM).
研究概览
研究类型
介入性
注册 (实际的)
105
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T2N 4N2
- Tom Baker Cancer Center
-
Edmonton、Alberta、加拿大、T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
Ottawa、Ontario、加拿大、K1Y 4E9
- Ottawa Health Research Institute - General Campus
-
-
Quebec
-
Montreal、Quebec、加拿大、H2L 4M1
- Notre Dame Centre Hospitalier de l'Universite de Montreal
-
-
-
-
-
Bangalore、印度、560027
- Bangalore Institute of Oncology
-
New Delhi、印度、110 029
- All India Institute of Medical Sciences
-
New Delhi、印度、110 085
- Rajiv Gandhi Cancer Institute & Research Center
-
-
Karnataka
-
Mysore、Karnataka、印度、570 017
- Bharath Hospital & Institute of Oncology
-
-
-
-
New South Wales
-
St Leonards、New South Wales、澳大利亚、2065
- Department of Haematology, Royal North Shore Hospital
-
-
South Australia
-
Adelaide、South Australia、澳大利亚、5000
- Institute of Medical & Veterinary Science
-
-
Victoria
-
East Melbourne、Victoria、澳大利亚、3002
- Peter MacCallum Cancer Centre
-
Melbourne、Victoria、澳大利亚、3181
- Clinical Haematology & BMT, Alfred Hospital
-
-
-
-
Arizona
-
Scottsdale、Arizona、美国、85259
- Mayo Clinic Arizona
-
-
California
-
La Jolla、California、美国、92037
- Scripps Clinic Medical Group, Inc.
-
-
Florida
-
Lecanto、Florida、美国、34461
- Cancer and Blood Disorders Center
-
-
Illinois
-
Chicago、Illinois、美国、60637
- University of Chicago
-
-
Maryland
-
Bethesda、Maryland、美国、20817
- Center for Cancer and Blood Disorders
-
-
Missouri
-
Jefferson City、Missouri、美国、65109
- Capitol Comprehensive Cancer Care Clinic
-
-
Nebraska
-
Omaha、Nebraska、美国、68114
- Nebraska Methodist Cancer Center
-
-
New York
-
Buffalo、New York、美国、14263
- Roswell Park Cancer Institute
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Diagnosed with multiple myeloma that is refractory or has relapsed after treatment
- Measurable serum and/or urine M-protein
- Failed 1 or 2 prior therapies for multiple myeloma
- 18 years of age or older
Exclusion Criteria:
- Received more than 2 prior therapies for multiple myeloma.
- Previous cancer therapies (chemotherapy, biologic therapy, radiation therapy or immunosuppressants) within the last 3 weeks
- Received monoclonal antibodies within the last 3 weeks (chimeric or murine) or 8 weeks (human or humanized)
- Received investigational (not yet approved by a regulatory authority) agent to treat multiple myeloma within the last 4 weeks
- Subjects who received a stem cell transplant using cells from themselves in the past 16 weeks
- Subjects who received a stem cell transplant using cells from another individual
- Previously treated with bortezomib or mapatumumab
- Known HIV, hepatitis-B, hepatitis-C, or hepatitis A infection
- Infection requiring antibiotics or hospitalization within the last 2 weeks
- Major surgery within the last 4 weeks
- Diagnosis with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes)
- History of other cancers within the past 5 years
- Pregnant or breast-feeding women
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:A
Bortezomib
|
1.3 mg/m^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle.
Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
其他名称:
|
|
实验性的:B-10
Bortezomib and Mapatumumab 10 mg/kg
|
1.3 mg/m^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle.
Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
其他名称:
10 mg/kg IV (in the vein), on day 1 of each 21-day cycle.
Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
20 mg/kg IV (in the vein), on day 1 of each 21-day cycle.
Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
|
|
实验性的:B-20
Bortezomib and Mapatumumab 20 mg/kg
|
1.3 mg/m^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle.
Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
其他名称:
10 mg/kg IV (in the vein), on day 1 of each 21-day cycle.
Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
20 mg/kg IV (in the vein), on day 1 of each 21-day cycle.
Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
To evaluate disease response to mapatumumab in combination with bortezomib and bortezomib alone
大体时间:17 cycles (up to a year)
|
17 cycles (up to a year)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
To evaluate the safety, including the frequency and severity of adverse events and laboratory abnormalities, of mapatumumab in combination with bortezomib and bortezomib alone throughout the study period
大体时间:17 cycles (up to a year)
|
17 cycles (up to a year)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 学习椅:GSK Clinical Trials、GlaxoSmithKline
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2006年5月1日
初级完成 (实际的)
2010年10月1日
研究完成 (实际的)
2010年10月1日
研究注册日期
首次提交
2006年4月17日
首先提交符合 QC 标准的
2006年4月17日
首次发布 (估计)
2006年4月19日
研究记录更新
最后更新发布 (估计)
2013年8月8日
上次提交的符合 QC 标准的更新
2013年8月1日
最后验证
2013年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.